Get started
Work

Eu/us/ctad Task Force: Lessons Learned From Recent and Current Alzheimer’s Prevention Trials

Year: 2017
Type: article
DOI: 10.14283/jpad.2017.13
Authors: P. Aisen, J. Touchon, R. Amariglio, S. Andrieu, R. Bateman, J. Breitner, M. Donohue, B. Dunn, R. Doody, N. Fox, S. Gauthier, M. Grundman, S. Hendrix, C. Ho, M. Isaac, R. Raman, P. Rosenberg, R. Schindler, L. Schneider, R.A. Sperling, P. Tariot, K. Welsh-Bohmer, M. Weiner, B. Vellas
Institutions: University of Southern California, Inserm, Neuropsychiatrie : Recherche Epidemiologique et Clinique, Centre Hospitalier Universitaire de Montpellier, Brigham and Women's Hospital, Harvard University, Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, Laboratoire Epidémiologie et Analyses en Santé Publique : Risques, Maladies Chroniques et Handicaps, Université de Toulouse, Washington University in St. Louis, McGill University, F. Hoffmann-La Roche AG, University College London, Denali Therapeutics (United States), European Medicines Agency, Johns Hopkins University, Pfizer (United States), Banner Alzheimer’s Institute, Duke University, University of California, San Francisco
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Biogen, aTyr, TauRx Pharmaceuticals, Eisai, H. Lundbeck A/S, Genentech, National Institute on Aging
OpenAlex ID: W2756405363
FWCI: 3.143
Cites: 42
Cited by: 42
Related to: 10